Clinical trial
Paclitaxel Poliglumex and Capecitabine in Treating Patients With Metastatic…
NCT00265733 · Alliance for Clinical Trials in Oncology, Other · Completed
Key facts
| NCT number | NCT00265733 |
|---|---|
| Title | Paclitaxel Poliglumex and Capecitabine in Treating Patients With Metastatic Breast Cancer |
| Official title | Phase II Trial of CT-2103 (Xyotax™) With Capecitabine as First-Line Chemotherapy for Patients With Metastatic Breast Cancer |
| Lead sponsor | Alliance for Clinical Trials in Oncology, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | capecitabine, paclitaxel poliglumex |
| Enrollment | 48 |
| Start date | Feb 1, 2006 |
| Primary completion | Aug 1, 2007 |
| Completion | May 1, 2013 |
| First posted | Dec 15, 2005 |
| Last update posted | Dec 6, 2016 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: